Back

Use of guideline directed medical therapy and clinical outcomes in cancer patients with de novo heart failure

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology - diagnostic and therapeutic advances Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Yusuf Ziya Sener

Erasmus University Rotterdam, Rotterdam (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Detecting global cardiac involvement in breast cancer: the GAVS index
Doctor C. Madaudo (Palermo, IT)
Abstract Slides Video
Presentation thumbnail
Echocardiographic indices of right ventricular function to predict cardiovascular outcomes in asian patients with cardiac amyloidosis
Doctor N. Sari (Jakarta, ID)
Abstract Slides Video
Presentation thumbnail
Bridging cancer and heart health: insights from a cardio-oncology consultation program at a tertiary university hospital
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology - diagnostic and therapeutic advances

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Impact of cancer therapies and cardiovascular risk factors on new-onset heart failure: insights from a cardio-oncology cohort
thumbnail
Congress Presentation
Clinical evaluation and outcome in patients with heart failure receiving chemotherapy with different anti-cancer agents
thumbnail
Congress Presentation
Does HFpEF represent a risk factor and a marker of cardiotoxicity in patients undergoing cancer treatment?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources